With our founders’ nearly 50 combined years of work in the gene therapy field, Renova Therapeutics is dedicated to creating definitive treatments for some of the world’s most common and debilitating chronic diseases – congestive heart failure and type 2 diabetes – and beyond.
Our Science
Our team’s collective experience drives our efforts to generate an entirely original platform of therapeutics and delivery systems that in a single dose may provide durable, life-long treatments for chronic diseases, including congestive heart failure and type 2 diabetes.
Our Lead Product (RT-100)
Our lead product candidate is a first-in-class, single-dose gene therapy designed to safely improve heart function through a one-time administration known as AC6 gene transfer, which involves infusing an inactivated adenovirus vector encoding human adenylyl cyclase type 6 (Ad5.hAC6) into the arteries that feed the heart during cardiac catheterization.
Our Paracrine Gene Therapy
Beyond RT-100, our novel approach to gene therapy involves safe, sustained systemic delivery of a therapeutic gene to the blood serum, where it can exert beneficial effects on target organs. This single-IV injection approach has most recently shown positive results in preclinical studies of congestive heart failure and type 2 diabetes.
